Nicotine e-cigarettes added to counseling improved abstinence at 12 weeks, but not at 24 weeks<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Nov. 12, 2020 (HealthDay News) — It is unclear whether the addition of nicotine electronic cigarettes to counseling leads to higher rates of smoking cessation than counseling alone among adults motivated to quit, according to the results of a study published in the Nov. 10 issue of the Journal of the American Medical Association<\/em>.<\/p>\n Mark J. Eisenberg, M.D., from McGill University in Montreal, and colleagues randomly assigned adults motivated to quit smoking from November 2016 to September 2019 at 17 Canadian sites to nicotine e-cigarettes (128 participants), non-nicotine e-cigarettes (127 participants), or no e-cigarettes (121 participants) for 12 weeks, with all receiving individual counseling. Self-reported smoking status was assessed at 12 and 24 weeks.<\/p>\n The researchers found that the point prevalence of abstinence was significantly greater for nicotine e-cigarettes plus counseling versus counseling alone at 12 weeks (21.9 versus 9.1 percent; risk difference [RD], 12.8; 95 percent confidence interval [CI], 4.0 to 21.6), but not 24 weeks (17.2 versus 9.9 percent; RD, 7.3; 95 percent CI, \u00e2\u0080\u00931.2 to 15.7). For non-nicotine e-cigarettes plus counseling versus counseling alone, the point prevalence for abstinence was not significantly different at 12 weeks (17.3 versus 9.1 percent; RD, 8.2; 95 percent CI, \u00e2\u0080\u00930.1 to 16.6) but was significantly greater at 24 weeks (20.5 versus 9.9 percent; RD, 10.6; 95 percent CI, 1.8 to 19.4). Adverse events were common for all groups (nicotine e-cigarette with counseling, 94 percent; non-nicotine e-cigarette with counseling, 93 percent; counseling only, 73 percent); cough (64 percent) and dry mouth (53 percent) were the most frequently reported.<\/p>\n “Trial interpretation is limited by early termination and inconsistent findings for nicotine and nonnicotine e-cigarettes, suggesting further research is needed,” the authors write.<\/p>\n Two authors disclosed financial ties to Pfizer.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n